Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 23 Oct 2023
FDA approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel for the treatment of acne vulgaris in patients twelve years of age and older
20 October 2023 - First and only FDA approved fixed dose, triple combination topical treatment. ...
Posted by Michael Wonder on 23 Oct 2023
Zydus receives US FDA approval for Zituvio to treat adult patients with type 2 diabetes mellitus
20 October 2023 - The company received final approval from the US FDA for its new drug application for Zituvio ...
Posted by Michael Wonder on 23 Oct 2023
1 November 2023 changes to the PBS listings of medicines for children and adolescents with chronic plaque psoriasis
23 October 2023 - On 1 November 2023, changes will be made to the authority requirements of the PBS listing ...
Posted by Michael Wonder on 22 Oct 2023
End of COVID-19 emergency response
20 October 2023 - A statement from Australia's Chief Medical Officer, Professor Paul Kelly, on the end of the COVID-19 emergency ...
Posted by Michael Wonder on 22 Oct 2023
We need a public option for pharmaceuticals
20 October 2023 - America is currently facing dual public health crises of record drug shortages and skyrocketing prices. ...
Posted by Michael Wonder on 22 Oct 2023
Should insurance cover Wegovy, Ozempic and other new weight loss drugs?
16 October 2023 - Insurance plans could cover blockbuster weight-loss medications such as Wegovy and Ozempic, but the benefits may not ...
Posted by Michael Wonder on 22 Oct 2023
US Food and Drug Administration approves BioMarin's Voxzogo (vosoritide) for children under 5 years with achondroplasia
20 October 2023 - Expanded indication in the US now includes children of all ages with achondroplasia. ...
Posted by Michael Wonder on 21 Oct 2023
Rezolute receives Priority Medicines (PRIME) eligibility from EMA for enhanced regulatory support of RZ358 in congenital hyperinsulinism
17 October 2023 - PRIME eligibility granted based on key positive data from the Phase 2B (RIZE) study and current ...
Posted by Michael Wonder on 21 Oct 2023
Brukinsa receives positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukaemia
20 October 2023 - BeiGene today announced that NICE of the United Kingdom has issued a final draft guidance recommending ...
Posted by Michael Wonder on 21 Oct 2023
FDA approves Penbraya, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
20 October 2023 - The FDA’s decision is based on data from Phase 2 and Phase 3 trials, which demonstrated that ...
Posted by Michael Wonder on 20 Oct 2023
FDA expands paediatric indication for entrectinib and approves new pellet formulation
20 October 2023 - Today, the FDA granted accelerated approval to entrectinib (Rozlytrek, Genentech) for paediatric patients older than 1 ...
Posted by Michael Wonder on 20 Oct 2023
Ethical and legal considerations in social media research for health technology assessment: conclusions from a scoping review
20 October 2023 - The objective was to identify and describe the published guidance and current academic discourse of ethical issues ...
Posted by Michael Wonder on 20 Oct 2023
Regeneron and Sanofi provide update on Dupixent (dupilumab) sBLA for chronic spontaneous urticaria
20 October 2023 - Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has issued a complete response letter for ...
Posted by Michael Wonder on 20 Oct 2023
Pfizer to price Covid drug Paxlovid at $1,390 per course
18 October 2023 - Health insurance plans will likely pay much less than the nearly $1,400 list price for Paxlovid, ...
Posted by Michael Wonder on 20 Oct 2023
Sumitomo Pharma and Pfizer in Canada receive Health Canada approval for Myfembree
19 October 2023 - Sumitomo Pharma Canada and Pfizer Canada today announced that Health Canada has granted a notice of compliance ...